Transcriptional basis for hepatic fibrosis in cystic fibrosis-associated liver disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 54, Issue 3, 2012, Pages 328-335

  Pereira, Tamara N ^a   Lewindon, Peter J ^a   Greer, Ristan M ^b   Hoskins, Anita C ^a   Williamson, Richard M ^b   Shepherd, Ross W ^a   Ramm, Grant A ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

cDNA array; cystic fibrosis liver disease; differential gene expression; hepatic fibrosis; hepatic stellate cell

Indexed keywords

CHEMOKINE; COLLAGEN; COMPLEMENTARY DNA; MATRIX METALLOPROTEINASE; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADOLESCENT; ARTICLE; BILE DUCT ATRESIA; CHILD; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; CYSTIC FIBROSIS ASSOCIATED LIVER DISEASE; DNA DETERMINATION; FEMALE; FIBROGENESIS; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD;

BILIARY ATRESIA; CASE-CONTROL STUDIES; CHEMOKINES; CHILD; CHOLESTASIS; COLLAGEN; CYSTIC FIBROSIS; GENE EXPRESSION; HUMANS; LIVER; LIVER CIRRHOSIS; MATRIX METALLOPROTEINASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PILOT PROJECTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSCRIPTION, GENETIC;

EID: 84857783398     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3182432034     Document Type: Article

References (30)

1. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245:1073-80. (Pubitemid 19231815)
2. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-73. (Pubitemid 19231814)
3. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989;245: 1059-65. (Pubitemid 19231813)
4. Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology 1999;30:1151-8. (Pubitemid 29510852)
5. Cystic Fibrosis Foundation Annual Data Base Report. Bethesda, MD: Cystic Fibrosis Foundation; 2008.
6. Sokol RJ, Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr 1999;28(suppl 1):S1-13.
7. Colombo C, Battezzati PM, Crosignani A, et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology 2002;36:1374-82. (Pubitemid 35403528)
8. Lewindon PJ, Shepherd RW, Walsh MJ, et al. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology 2011;53:193-201.
9. Kinnman N, Lindblad A, Housset C, et al. Expression of cystic fibrosis transmembrane conductance regulator in liver tissue from patients with cystic fibrosis. Hepatology 2000;32:334-40. (Pubitemid 30616012)
10. Smith JL, Lewindon PJ, Hoskins AC, et al. Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis. Hepatology 2004;39:1673-82. (Pubitemid 38702669)
11. Ramm GA, Shepherd RW, Hoskins AC, et al. Fibrogenesis in pediatric cholestatic liver disease: role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment. Hepatology 2009;49:533-44.
12. Lewindon PJ, Pereira TN, Hoskins AC, et al. The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease. Am J Pathol 2002;160:1705-15. (Pubitemid 34525650)
13. Pereira TN, Lewindon PJ, Smith JL, et al. Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease. J Hepatol 2004;41:576-83. (Pubitemid 39297792)
14. Leonardi S, Giambusso F, Sciuto C, et al. Are serum type III procollagen and prolyl hydroxylase useful as noninvasive markers of liver disease in patients with cystic fibrosis? J Pediatr Gastroenterol Nutr 1998;27:603-5. (Pubitemid 28492265)
15. Bartlett JR, Friedman KJ, Ling SC, et al. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009;302:1076-83.
16. Shackel NA, McGuinness PH, Abbott CA, et al. Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression. Gut 2001;49:565-76. (Pubitemid 32896989)
17. Honda M, Kaneko S, Kawai H, et al. Differential gene expression between chronic hepatitis B and C hepatic lesion. Gastroenterology 2001;120:955-66. (Pubitemid 32193192)
18. Shackel NA, McGuinness PH, Abbott CA, et al. Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am J Pathol 2002;160: 641-54. (Pubitemid 34160342)
19. Bezerra JA, Tiao G, Ryckman FC, et al. Genetic induction of proinflammatory immunity in children with biliary atresia. Lancet 2002;360:1653-9. (Pubitemid 35379738)
20. Chen L, Goryachev A, Sun J, et al. Altered expression of genes involved in hepatic morphogenesis and fibrogenesis are identified by cDNA microarray analysis in biliary atresia. Hepatology 2003;38:567-76. (Pubitemid 37052144)
21. Zhang DY, Sabla G, Shivakumar P, et al. Coordinate expression of regulatory genes differentiates embryonic and perinatal forms of biliary atresia. Hepatology 2004;39:954-62. (Pubitemid 38428934)
22. Scheuer PJ. Liver biopsy size matters in chronic hepatitis: bigger is better. Hepatology 2003;38:1356-8. (Pubitemid 37466959)
23. Scheuer PJ, Standish RA, Dhillon AP. Scoring of chronic hepatitis. Clin Liver Dis 2002;6:335-47. (Pubitemid 34755895)
24. Ramm GA. Chemokine (C-C motif) receptors in fibrogenesis and hepatic regeneration following acute and chronic liver disease. Hepatology 2009;50:1664-8.
25. Kruithof EK. Plasminogen activator inhibitors-a review. Enzyme 1988;40:113-21.
26. Inuzuka S, Ueno T, Torimura T, et al. The significance of colocalization of plasminogen activator inhibitor-1 and vitronectin in hepatic fibrosis. Scand J Gastroenterol 1997;32:1052-60. (Pubitemid 27433670)
27. Fitch P, Bennett B, Booth NA, et al. Distribution of plasminogen activator inhibitor in normal liver, cirrhotic liver, and liver with metastases. J Clin Pathol 1994;47:218-21. (Pubitemid 24120682)
28. Wang H, Vohra BP, Zhang Y, et al. Transcriptional profiling after bile duct ligation identifies PAI-1 as a contributor to cholestatic injury in mice. Hepatology 2005;42:1099-108. (Pubitemid 43112677)
29. Bergheim I, Guo L, Davis MA, et al. Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J Pharmacol Exp Ther 2006;316:592-600. (Pubitemid 43130985)
30. Higuchi H, Gores GJ. Bile acid regulation of hepatic physiology: IV. Bile acids and death receptors. Am J Physiol Gastrointest Liver Physiol 2003;284:G734-8. (Pubitemid 36437972)